Evelo Biosciences (NASDAQ: EVLO) is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. Cells in the small intestine are known to play a central role in governing the body’s immune, metabolic, and neurological systems.

Evelo Biosciences has created an integrated platform to develop a range of oral biologics which harness this central role, and the efficiency of their platform has allowed Evelo to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases, including the treatment of COVID-19 and many cancers.

These orally delivered, room-temperature stable therapies are single strains of microbes selected for defined pharmacological properties. They have been observed to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo Biosciences has also observed that specific microbes can down- or up-regulate immune responses throughout the body by acting on cells in the small intestine.

In 2019, the JIMCO Life Sciences Fund participated in a Series B post-IPO equity investment in Evelo, and in parallel, Jameel Health agreed a strategic collaboration to develop and commercialize Evelo’s novel therapy EDP1815 – if approved by relevant health authorities – for inflammatory diseases including COVID-19 in select developing markets in the Middle East, Türkiye, and Africa, serving over 1.7 billion people.

Visit: Evelo Biosciences